Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of DS010 in Patients With Cancer Cachexia

NCT07530666 is registered in ClinicalTrials.gov with Dartsbio Pharmaceuticals Ltd. as lead sponsor.

NCT NCT07530666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07530666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of DS010 in Patients With Cancer Cachexia
Lead sponsor
Dartsbio Pharmaceuticals Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
April 30, 2028
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cachexia, cancer